SCHEDULE: State Street Discloses 5.1% Stake in TG Therapeutics
Beneficial Ownership Report (Schedule 13G)
State Street Corporation has reported a 5.1% beneficial ownership stake in TG Therapeutics Inc., totaling 8,100,619 shares of common stock.
Summary
- State Street Corporation, a Massachusetts-based parent holding company, has filed a Schedule 13G indicating beneficial ownership in TG Therapeutics Inc.
- The filing reports an aggregate beneficial ownership of 8,100,619 shares of TG Therapeutics common stock.
- This ownership represents 5.1% of the class of securities.
- State Street Corporation holds shared voting power over 7,634,700 shares and shared dispositive power over 8,100,619 shares.
- The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 6
Explanation: The filing is a factual disclosure of beneficial ownership. The presence of a significant institutional investor like State Street can be viewed as a slightly positive signal, indicating institutional interest and liquidity, though it does not provide operational or financial performance insights.
Positives
- Significant institutional ownership by State Street Corporation, a major financial institution, may signal confidence in TG Therapeutics.
- The holding is stated to be in the ordinary course of business, indicating a passive investment rather than an activist stance.
Future Outlook
NA
Industry Context
This filing reflects a standard disclosure of significant passive ownership by a large institutional investor, State Street Corporation, in a publicly traded company, TG Therapeutics Inc. Such disclosures are common and provide transparency into institutional holdings, which can be a factor in market sentiment and liquidity for the issuer's stock.
Stakeholder Impact
- Shareholders: Increased transparency regarding institutional ownership and potential for enhanced liquidity due to a large institutional holder.
Key Dates
| Date | Description |
|---|---|
| 09/30/2025 | Date of event which requires the filing of this statement |
| 11/07/2025 | Signature date of the filing by State Street Corporation |
Keywords
State Street Corporation, TG Therapeutics Inc, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor, Equity Stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.